A Simple Synthesis of 6-Phenylpyrano[2,3-c]pyrazol-4(1H)-ones

Wilfried Becker, Gernot A. Eller, Wolfgang Holzer*

Department of Drug Synthesis, University of Vienna, Althanstrasse 14, 1090 Vienna, Austria Fax +43(1)42779556; E-mail: wolfgang.holzer@univie.ac.at Received 14 February 2005; revised 4 April 2005

Abstract: A novel synthesis of substituted 6-phenylpyrano[2,3c]pyrazol-4(1H)-ones via reaction of various 2-substituted or 2,5disubstituted 2,4-dihydro-3H-pyrazol-3-ones with phenylpropynoyl chloride using calcium hydroxide in refluxing 1,4-dioxane is described. N-Unsubstituted representatives were obtained by treatment of 4-methoxybenzyl-protected congeners with trifluoroacetic acid.

Key words: pyrazolones, acylations, cyclizations, fused-ring systems, PMB protecting group



Figure 1

The 6-phenylpyrano[2,3-c]pyrazol-4(1H)-one moiety **1** is an interesting heterocyclic system as it represents a pyrazole analogue of flavone (2-phenyl-4H-chromen-4-one), the latter being the parent system for a large variety of natural products which play important roles in numerous biological processes (Figure 1).¹ Few representatives of type 1 are hitherto known (for instance 1b,² 1g,³ 1h,⁴⁻⁷ $1x^7$, $1y^5$); reported pathways for their synthesis are displayed in Scheme 1. Accordingly, derivatives 1g, 1h, 1x, and 1y have been obtained by acid-catalyzed cyclization of 1,3-diketones 4^{3-7} the latter being available either from 2-pyrazolin-5-ones 2 by acetylation and subsequent Claisen condensation^{4,7} [or treatment with lithium bis(trimethylsilyl)amide/benzoyl chloride]^{3,6} or via ringtransformation of phenylhydrazone 6 derived from 3acetyl-4-hydroxy-6-phenyl-2H-pyran-2-one (5).^{5,6} Alternatively, reaction of 4-cinnamoyl-5-hydroxypyrazoles 7 with bromine followed by treatment of the resulting bro-



b: R¹ = Me, R³ = Me; g: R¹ = Ph, R³ = H; h: R¹ = Ph, R³ = Me; x: R¹ = Me, R³ = Ph; y: R¹ = Ph, R³ = Ph

Scheme 1 Known methods for the synthesis of the title compounds 1

SYNTHESIS 2005, No. 15, pp 2583-2589 Advanced online publication: 20.07.2005 DOI: 10.1055/s-2005-872078; Art ID: T01805SS © Georg Thieme Verlag Stuttgart · New York

2583

mo compounds **8** with DBU afforded $1b^2$ and 1h,⁶ respectively. However, these traditional preparations are multistep reactions characterized by poor overall yields.

In the benzene series, an interesting strategy for the synthesis of substituted flavones **11** consists of a basecatalyzed 6-*endo-dig* cyclization of *o*-phenylpropynoylphenols **10**.^{8–11} Strongly dependent on the reaction conditions, the formation of 5-*exo-dig* product **11a** (aurones) is also possible.^{8,11} The starting phenylpropynoyl compounds **10** are available, for instance, by photo-Fries rearrangement of aryl phenylpropynoates **9** (Scheme 2).^{8,9}



Scheme 2 Synthesis of flavones by cyclization of *ortho*-phenylpropynoylphenols

We herein, wish to report a straightforward synthesis of various 6-phenylpyrano[2,3-*c*]pyrazol-4(1*H*)-ones **1** following a related approach. It includes acylation of pyrazolones **2** with phenylpropynoyl chloride following the general procedure described by Jensen [RCOCl, Ca(OH)₂, refluxing dioxane]¹² in order to obtain the corresponding 4-phenylpropynoyl-substituted 5-hydroxypyrazoles of type **12**. Subsequently, the latter could be cyclized into target compounds **1** (Scheme 3).

However, it turned out that even under the acylation conditions pyran ring-closure into 1 occurred. For this reason, apparent intermediates 12 were not isolated and cyclization was completed with prolonged reaction times (six hours instead of two hours for a 'normal' Jensen-acylation). After reaction of *N*-methylpyrazolone 2b with phenylpropynoyl chloride the crude product still contained 50% of non cyclized intermediate 12b. Nevertheless, cyclization to 1b could be obtained smoothly, by subsequent treatment of this mixture with potassium carbonate in anhydrous acetone. Although yields are average, the presented approach leads to the desired 6-phenylpyrano[2,3*c*]pyrazol-4(1*H*)-ones 1 in a quick and simple reaction and thus seems to be superior and much more convenient than those hitherto used syntheses.

Reaction of pyrazolone **2i** with phenylpropynoyl chloride represents a special case: the intermediate 3,5-dihydroxy-4-phenylpropynoylpyrazole (**12i**) can either cyclize into the 3-hydroxy-1,6-diphenylpyrano[2,3-c]pyrazol-4(1H)one (**1i**) or – upon attack of 3-OH on the alkyne triple





Scheme 3 Novel one-pot synthesis of 6-phenylpyrano[2,3-*c*]pyra-zol-4(1*H*)-ones

bond – into the isomeric 3-hydroxy-2,6-diphenylpyrano[2,3-c]pyrazol-4(2*H*)-one (**13**; Scheme 4). Isomers **1i** and **13** are difficult to discriminate on the basis of their spectroscopic properties. However, NOE-difference experiments and NOESY spectra unambiguously revealed the structure of **1i** as the isolated reaction product. Accordingly, a clear NOE on the signal of NPh-H-2,6 protons upon irradiation of the CPh-H-2,6 transition (and, reversely, on the signal of CPh-H-2,6 upon disturbing the NPh-H-2,6 transition) provides proof of the spatial proximity of the two phenyl rings and thus the 4(1*H*)-one structure (Scheme 4). In contrast, the corresponding phenyl protons in **13** are too far apart for an NOE to be detected.



Scheme 4

Recently, we presented the application of the 4-methoxybenzyl (PMB) protecting group in the synthesis of N-unsubstituted 4-acylpyrazolones.¹³ This protecting group resists the conditions of primary pyrazolone ring synthesis as well as those of 4-acylation under the 'Jensen' conditions and, moreover, it can be conveniently removed by the action of trifluoroacetic acid. Similarly, i.e. by treatment of 1-PMB-substituted compounds **1e** and **1f** with trifluoroacetic acid, the N-unsubstituted bicyclic target compounds **14e** and **14f** were easily available (Scheme 5). Compound **14e** represents the 'parent' pyrazole analogue of flavone.



Scheme 5

Detailed NMR spectroscopic investigations in DMSO- d_6 solution revealed 14e to be involved in prototropic tautomerism resulting in an equilibrium between the 1Hform A and 2H-form B (Figure 2). This mainly follows from the magnitude of the geminal spin-coupling constant $^{2}J(C-3a,H-3)$. Corresponding coupling constants have been shown to be sensitive probes for discrimination between forms having an 'intact' lone-pair at N-2 and those characterized by an N2-H (N2-R) substructure.¹⁴ In the case of **14e** this coupling $(^{2}J = 8.6 \text{ Hz})$ is significantly reduced compared to ${}^{2}J(C-3a,H-3)$ in the corresponding N-1 substituted 3-H congeners 1a, 1c, 1e, and 1g (10.1–10.5 Hz). This situation closely resembles that of pyrazole, where - due to fast prototropic exchange - the observed geminal ¹³C,¹H coupling (${}^{2}J = 9.9$ Hz, in CDCl₃) represents a mean value between the larger ${}^{2}J(C-4,H-3)$ coupling and the smaller ${}^{2}J(C-4,H-5)$ one, 15,16 whereas in

Table 1¹H NMR Data of Compounds 1a-j and 14e,f

'fixed' 1-phenylpyrazole the pyrazole C-4 atom is involved in two different geminal couplings $[{}^{2}J(C-4,H-3) = 10.3 \text{ Hz}, {}^{2}J(C-4,H-5) = 8.1 \text{ Hz}]$ (Figure 2).¹⁷

Moreover, an NOE on the signal of H-3 upon irradiation of the NH transition additionally hints at a contribution of the 2H-form **B** to the structure of **14e** (Figure 2).



Figure 2 Prototropic tautomerism in pyrazole and in 14e

Detailed NMR analyses for all prepared compounds were undertaken, considering also characteristic ${}^{13}C$, ¹H spincoupling constants as well as ${}^{15}N$ NMR chemical shifts. Owing to their low solubility in CDCl₃, the spectra of compounds **1i**, **14e**, and **14f** were recorded in DMSO-*d*₆ solutions. The data obtained show a high degree of consistency and are summarized in Table 1 (¹H NMR), Table 2 (¹³C NMR chemical shifts), Table 3 (¹³C, ¹H coupling constants), and Table 4 (¹⁵N NMR chemical shifts).

Compd	Solvent	H of R ¹	H of R ³	H-5	H of 6-Ph
1a	CDCl ₃	4.00 (Me)	7.96 (H-3)	6.66	7.81 (2,6), 7.53 (3,4,5)
1b	CDCl ₃	3.90 (Me)	2.55 (Me)	6.59	7.79 (2,6), 7.51 (3,4,5)
1c	CDCl ₃	7.38 (Ph-2,3,4,5,6), 5.48 (NCH ₂)	8.02 (H-3)	6.65	7.71 (2,6), 7.51 (3,4,5)
1d	CDCl ₃	7.36 (Ph-2,3,4,5,6), 5.39 (NCH ₂)	2.58 (Me)	6.59	7.69 (2,6), 7.50 (3,4,5)
1e	CDCl ₃	7.33 (Ph-2,6), 6.90 (Ph-3,5), 5.41 (NCH ₂), 3.79 (OMe)	7.99 (H-3)	6.64	7.73 (2,6), 7.53 (3,4,5)
1f	CDCl ₃	7.31 (Ph-2,6), 6.89 (Ph-3,5), 5.32 (NCH ₂), 3.78 (OMe)	2.57 (Me)	6.59	7.71 (2,6), 7.51 (3,4,5)
1g	CDCl ₃	7.89 (Ph-2,6), 7.59 (Ph-3,5), 7.45 (Ph-4)	8.18 (H-3)	6.77	7.82 (2,6), 7.53 (3,4,5)
1h	CDCl ₃	7.86 (Ph-2,6), 7.56 (Ph-3,5), 7.40 (Ph-4)	2.66 (Me)	6.77	7.80 (2,6), 7.53 (3,4,5)
1i	DMSO- d_6	7.83 (Ph-2,6), 7.60 (Ph-3,5), 7.39 (Ph-4)	11.53 (OH)	6.83	7.94 (2,6), 7.57 (3,4,5)
1j	CDCl ₃	7.85 (Ph-2,6), 7.55 (Ph-3,5), 7.36 (Ph-4)	4.13 (OMe)	6.70	7.78 (2,6), 7.53 (3,4,5)
14e	DMSO- d_6	13.80 (NH)	8.45 (H-3)	6.75	7.99 (2,6), 7.56 (3,4,5)
14f	DMSO- d_6	13.40 (NH)	2.53 (Me)	6.66	7.95 (2,6), 7.53 (3,4,5)

 Table 2
 ¹³C NMR Chemical Shifts of Compounds 1a–j and 14e,f (Solvents as in Table 1)

Compd	C-3	C-3a	C-4	C-5	C-6 C-7a C of 6-Ph				$C \text{ of } R^1$	C of R ³		
							C-1	C-2,6	C-3,5	C-4		
1a	134.3	107.4	174.8	109.4	160.0	153.9	130.7	126.0	129.2	131.5	34.3 (Me)	_
1b	145.4	105.5	175.6	109.6	159.7	154.1	130.9	125.9	129.1	131.1	33.8 (Me)	13.8 (Me)
1c	134.6	107.8	174.8	109.5	160.1	153.8	130.8	126.0	129.1	131.5	52.1 (NCH ₂), Ph: 134.7 (1), 129.0 (3,5), 128.6 (4), 127.9 (2,6)	-
1d	145.8	105.9	175.6	109.7	159.8	154.0	130.9	125.9	129.1	131.3	51.7 (NCH ₂), Ph: 135.0 (1), 129.0 (3,5), 128.4 (4), 127.8 (2,6)	13.9 (Me)
1e	134.5	107.7	174.8	109.4	160.0	153.6	130.8	126.0	129.1	131.5	55.3 (OMe), 51.7 (NCH ₂), Ph: 159.8 (4), 129.4 (2,6), 126.7 (1), 114.4 (3,5)	-
1f	145.7	105.9	175.6	109.7	159.7	153.8	131.0	125.9	129.1	131.3	55.3 (OMe), 51.2 (NCH ₂), Ph: 159.6 (4), 129.3 (2,6), 127.1 (1), 114.3 (3,5)	13.9 (Me)
1g	135.7	108.9	174.8	109.8	160.5	153.1	130.7	126.1	129.3	131.7	Ph: 137.0 (1), 129.6 (3,5), 127.9 (4), 121.3 (2,6)	-
1h	147.0	107.0	175.6	109.9	160.4	153.3	130.8	126.0	129.2	131.5	Ph: 137.0 (1), 129.5 (3,5), 127.5 (4), 121.1 (2,6)	13.9 (Me)
1i	151.8	96.4	173.2	109.3	159.3	156.1	130.4	126.0	129.2	131.4	Ph: 136.6 (1), 129.6 (3,5), 126.7 (4), 120.6 (2,6)	_
1j	157.8	97.1	174.0	110.0	160.1	152.5	130.7	125.9	129.3	131.5	Ph: 137.1 (1), 129.5 (3,5), 126.9 (4), 120.6 (2,6)	56.2 (OMe)
14e	127.1	107.1	175.9	107.2	161.2	161.6	131.3	126.3	129.2	131.5	_	-
14f	138.6	104.6	176.7	107.1	161.0	161.6	131.3	126.1	129.0	131.3	_	10.9 (Me)

In conclusion, we have presented a simple and straightforward one-pot synthesis for the title compounds which is advantageous compared to the hitherto used methods.

Moreover, detailed NMR data material concerning 6-phenylpyrano[2,3-c]pyrazol-4(1H)-ones was provided.

 Table 3
 Selected ¹³C,¹H Spin-Coupling Constants (Hz) of 1a-j and 14e,f (Solvents as in Table 1)

Compd	${}^{1}J(C-3,H-3)$ ${}^{1}J(3-Me)$	⁴ <i>J</i> (C-3,H-5)	$^{2}J(C-3a,H-3)$ $^{3}J(C-3a,3-Me)$	³ <i>J</i> (C-3a,H-5)	² <i>J</i> (C-4,H-5)	$^{1}J(C-5,H-5)$	Other Couplings
1a	194.3	1.4	10.1	4.1	2.0	165.5	${}^{1}J(\text{NMe}) = 141.6$
1b	129.0	1.5	2.8	4.2	2.1	164.9	${}^{1}J(NMe) = 141.3, {}^{2}J(C-3,3-Me) = 7.1, {}^{3}J(C-7a,NMe) = 2.3$
1c	194.5	1.3	10.5	4.3	2.0	165.4	${}^{1}J(\text{NCH}_{2}) = 141.2$
1d	129.0	1.5	2.6	4.1	2.1	165.0	${}^{1}J(\text{NCH}_{2}) = 140.5,$ ${}^{2}J(\text{C3},3\text{-Me}) = 7.1,$ ${}^{3}J(\text{C-7a},\text{NCH}_{2}) = 2.6$
1e	194.1	1.5	10.1	4.3	2.1	165.4	${}^{1}J(NCH_{2}) = 140.8, {}^{3}J(C-7a,NCH_{2}) = 2.5, {}^{3}J(C-7a,H-3) = 5.2, {}^{1}J(OMe) = 143.9$

Compd	${}^{1}J(C-3,H-3)$ ${}^{1}J(3-Me)$	⁴ <i>J</i> (C-3,H-5)	${}^{2}J(C-3a,H-3)$ ${}^{3}J(C-3a,3-Me)$	³ <i>J</i> (C-3a,H-5)	$^{2}J(C-4,H-5)$	${}^{1}J(C-5,H-5)$	Other Couplings
1f	128.9	1.5	2.8	4.2	2.1	165.0	${}^{1}J(\text{NCH}_{2}) = 140.5, {}^{2}J(\text{C-3},3-\text{Me}) = 7.1, {}^{3}J(\text{C-7a},\text{NCH}_{2}) = 2.5,$ ${}^{1}J(\text{OMe}) = 144.0$
1g	194.9	1.5	10.3	4.4	2.1	165.8	$^{3}J(C-7a,H-3) = 5.0$
1h	129.2	1.4	2.8	4.0	2.0	165.6	$^{2}J(C-3,3-Me) = 7.1$
1i	_	<0.5	_	4.0	1.9	166.7	
1j	_	1.4	-	4.3	2.0	166.1	${}^{1}J(OMe) = 146.9, {}^{3}J(C-3,OMe) = 4.0, {}^{3}J(C-6,H-5) = 7.4, {}^{3}J(Ph-C1,H-5) = 2.6$
14e	194.5		8.6	4.5	1.8	165.5	${}^{3}J(C-7a,H-3) = 8.5, {}^{2}J(C-6,H-5) = 6.6, {}^{3}J(Ph-C1,H-5) = 2.9$
14f	130.1		2.9	4.5	1.8	165.4	${}^{2}J(C-3,3-Me) = 7.1, {}^{2}J(C-6,H-5) = 6.7, {}^{3}J(Ph-C1,H-5) = 2.9$

 Table 3
 Selected ¹³C,¹H Spin-Coupling Constants (Hz) of 1a-j and 14e,f (Solvents as in Table 1) (continued)

Table 4 ¹⁵N NMR Chemical Shifts of 1a-j

Compd	Solvent	N-1	N-2	Compd	Solvent	N-1	N-2
1a	CDCl ₃	-205.1	-85.9	1f	CDCl ₃	-198.5	-93.4
1b	CDCl ₃	-211.9	-92.9	1g	CDCl ₃	-186.4	-88.0
1c	CDCl ₃	-193.5	-86.5	1h	CDCl ₃	-192.5	-94.7
1d	CDCl ₃	-200.2	-93.2	1i	DMSO- d_6	-211.3	not found
1e	CDCl ₃	-191.7	-86.7	1j	CDCl ₃	-210.1	not found

Melting points were determined on a Reichert-Kofler hot-stage microscope and are uncorrected. Mass spectra were obtained on a Shimadzu QP 1000 instrument (EI, 70 eV). IR spectra were recorded on a Perkin-Elmer FTIR 1605 spectrophotometer. ¹H and ¹³C NMR spectra were recorded on a Varian UnityPlus 300 spectrometer $(299.95 \text{ MHz for }^{1}\text{H}, 75.43 \text{ MHz for }^{13}\text{C})$ at 28 °C. The center of the solvent signal was used as an internal standard which was related to TMS with $\delta = 7.26$ ppm (¹H in CDCl₃), $\delta = 2.49$ ppm (¹H in DMSO d_6), $\delta = 77.0$ ppm (¹³C in CDCl₃), and $\delta = 39.5$ ppm (¹³C in DMSO d_6). ¹⁵N NMR spectra were obtained on a Bruker Avance 500 instrument with a 'directly' detecting broadband observe probe and were referenced against external nitromethane (coaxial capillary). Full and unambiguous assignment for all NMR signals was achieved by combined application of standard NMR techniques such as fully ¹Hcoupled ¹³C NMR (gated decoupling), APT, 1D-TOCSY, NOE-difference, NOESY, HMQC, gs-HSQC, gs-HMBC, and selective long-range INEPT in a 1D and a 2D version.¹⁶ The following commercially non available pyrazolones were prepared according to the literature: 2a,¹⁸ 2b,¹⁹ 2c,³ 2d,²⁰ 2e,¹³ 2g,²¹ 2i,²² 2j.²³ Yields of products 1 were not optimized.

3-Phenylprop-2-ynoyl Chloride²⁴

Under anhyd conditions, to a soln of phenylpropiolic acid (10.0 g, 68.4 mmol) in CH_2Cl_2 (260 mL) was added $SOCl_2$ (24.4 g, 205 mmol) and the resulting mixture was stirred at 40 °C for 16 h. Then the solvent and excess $SOCl_2$ were removed under reduced pressure and the oily residue was subjected to vacuum distillation to afford 9.0 g (80%) of a colorless oil.

Bp 76-78 °C/1.3 mbar.

¹H NMR (CDCl₃): δ = 7.64 (m, 2 H, Ph-2,6), 7.56 (m, 1 H, Ph-4), 7.43 (m, 2 H, Ph-3,5).

¹³C NMR (CDCl₃): δ = 149.5 (C=O), 133.7 (Ph-2,6), 132.2 (Ph-4), 128.9 (Ph-3,5), 118.0 (Ph-1), 94.1 (PhC=), 84.1 (=CCO).

2-(4-Methoxybenzyl)-5-methyl-2,4-dihydro-3H-pyrazol-3-one $(2f)^{25}$

Under cooling with an ice bath, 4-methoxybenzylhydrazine (1.52 g, 10 mmol) (prepared according to literature procedures¹³) was added slowly to ethyl acetoacetate (1.30 g, 10 mmol). After stirring for 30 min at 0 °C, the mixture was suction filtered and the remaining solid was washed with cold Et₂O (3 mL) to afford 1.64 g (75%) of a colorless powder.

Mp 128-130 °C.

 ^1H NMR (CDCl_3): δ = 7.27 (m, 2 H, Ph-2,6), 6.85 (m, 2 H, Ph-3,5), 4.72 (s, 2 H, NCH_2), 3.78 (s, 3 H, OMe), 3.18 (s, 2 H, pyrazole H-4), 2.05 (s, 3 H, 5-Me).

¹³C NMR (CDCl₃): δ = 171.9 [pyrazole C-3, ²*J*(C-3,H-4) = 5.1 Hz, ³*J*(C-3,NCH₂) = 2.1 Hz], 159.1 (Ph-4), 155.6 [pyrazole C-5, ²*J*(C-5,5-Me) = 7.6 Hz), ²*J*(C-5,H-4) = 5.2 Hz], 129.6 (Ph-2,6), 128.8 (Ph-1), 114.0 (Ph-3,5), 55.2 (OMe, ¹*J* = 143.7 Hz), 47.2 (NCH₂, ¹*J* = 138.9 Hz), 41.6 [pyrazole C-4, ¹*J* = 133.0 Hz, ³*J*(C-4,5-Me) = 2.9 Hz], 17.0 (5-Me, ¹*J* = 128.9 Hz).

¹⁵N NMR (CDCl₃): $\delta = -55.7$ (N-1), -192.4 (N-2).

6-Phenylpyrano[2,3-c]pyrazol-4(1*H*)-ones 1; General Procedure

A solution of phenylpropynoyl chloride (823 mg, 5 mmol) in anhyd 1,4-dioxane (3 mL) was added dropwise to a mixture of the appropriate pyrazolone **2** (5 mmol), Ca(OH)₂ (741 mg, 10 mmol), and anhyd 1,4-dioxane (10 mL). The resulting mixture was heated at reflux for 6 h. After cooling to r.t., the mixture was treated with 2 N HCl (20 mL) and then stirred for 1 h before it was poured onto H₂O (50 mL). After 30 min, the mixture was suction filtered, the remaining solid was repeatedly washed with H₂O, and purified as outlined below. It should be mentioned that the crude products in most cases were accompanied by small amounts of highly colored by-products.

1-Methyl-6-phenylpyrano[2,3-c]pyrazol-4(1H)-one (1a)

The crude product (416 mg) was subjected to flash chromatography (silica gel, EtOAc) and subsequently recrystallized (EtOH– H_2O) to afford 166 mg (15%) of a brownish solid.

Mp 165 °C.

IR (KBr): 1643 cm⁻¹ (C=O).

MS: *m*/*z* (%) = 227 (M⁺ + 1, 10), 226 (M⁺, 57), 124 (100), 102 (21), 53 (16), 43 (15).

Anal. Calcd for $C_{13}H_{10}N_2O_2$ (226.23): C, 69.02; H, 4.46; N, 12.38. Found: C, 68.77; H, 4.66; N, 12.16.

1,3-Dimethyl-6-phenylpyrano[2,3-c]pyrazol-4(1H)-one (1b)

The crude product (793 mg) consisted of a 1:1 mixture of **1b** and **12b**.

To the crude product was added K_2CO_3 (235 mg, 1.7 mmol) and anhyd acetone (60 mL) and the suspension was refluxed for 3.5 h with stirring. After filtration, the filtrate was evaporated under reduced pressure to afford 789 mg (66%) of **1b** as a yellowish powder (pure according to NMR analysis).

In another run the crude product was recrystallized (EtOH– H_2O) affording 204 mg (17%) of **1b** as yellow crystals.

Mp 197 °C (Lit.2 197-198 °C).

1-Benzyl-6-phenylpyrano[2,3-c]pyrazol-4(1H)-one (1c)

Recrystallization (EtOH–H₂O) afforded 333 mg (22%) of brownish crystals.

Mp 178–179 °C.

IR (KBr): 1634 cm⁻¹ (C=O).

MS: m/z (%) = 303 (M⁺ + 1, 13), 302 (M⁺, 77), 172 (54), 144 (52), 91 (100), 65 (31).

Anal. Calcd for $C_{19}H_{14}N_2O_2$ (302.30): C, 75.48; H, 4.67; N, 9.27. Found: C, 75.20; H, 4.58; N, 9.26.

1-Benzyl-3-methyl-6-phenylpyrano[2,3-c]pyrazol-4(1*H*)-one (1d)

Recrystallization (EtOH– H_2O) afforded 554 mg (35%) of brownish crystals.

Mp 189-190 °C.

IR (KBr): 1653 cm⁻¹ (C=O).

$$\begin{split} \text{MS:} \ m/z \ (\%) &= 317 \ (\text{M}^+ + 1, \, 19), \, 316 \ (\text{M}^+, \, 81), \, 225 \ (37), \, 186 \ (22), \\ 158 \ (27), \, 91 \ (100), \, 67 \ (23), \, 65 \ (25). \end{split}$$

Anal. Calcd for $C_{20}H_{16}N_2O_2$ (316.35): C, 75.93; H, 5.10; N, 8.85. Found: C, 75.73; H, 5.15; N, 8.78.

1-(4-Methoxybenzyl)-6-phenylpyrano[2,3-c]pyrazol-4(1*H*)-one (1e)

Recrystallization (EtOH) afforded 376 mg (23%) of pink crystals. Mp 220 $^{\circ}$ C.

Synthesis 2005, No. 15, 2583–2589 $\hfill {\ensuremath{\mathbb C}}$ Thieme Stuttgart \cdot New York

IR (KBr): 1639 cm⁻¹ (C=O)

MS: m/z (%) = 332 (M⁺, 4), 240 (43), 138 (100), 70 (20), 69 (25), 67 (19), 43 (20).

Anal. Calcd for $C_{20}H_{16}N_2O_3$ (332.35): C, 72.28; H, 4.85; N, 8.43. Found: C, 72.00; H, 4.88; N, 8.38.

1-(4-Methoxybenzyl)-3-methyl-6-phenylpyrano[2,3-c]pyrazol-4(1*H*)-one (1f)

Recrystallization (EtOH–H₂O) afforded 800 mg (46%) of pale pink crystals.

Mp 188 °C.

IR (KBr): 1647 cm⁻¹ (C=O).

MS: *m*/*z* (%) = 346 (M⁺, 26), 121 (100).

Anal. Calcd for $C_{21}H_{18}N_2O_3$ (346.38): C, 72.82; H, 5.24; N, 8.09. Found: C, 72.55; H, 5.05; N, 8.36.

1,6-Diphenylpyrano[2,3-c]pyrazol-4(1H)-one (1g)

Recrystallization (EtOH) afforded 878 mg (61%) of beige crystals. Mp 189 °C (Lit.³ 190 °C).

3-Methyl-1,6-diphenylpyrano[2,3-c]pyrazol-4(1*H*)-one (1h)

Recrystallization (EtOH–H₂O) afforded 854 mg (57%) of tan-colored crystals.

Mp 208-209 °C (Lit.4 210-211 °C, Lit.5 209-210 °C).

$$\begin{split} \text{MS:} \ m/z \ (\%) &= 303 \ (\text{M}^+ + 1, 11), \ 302 \ (\text{M}^+, 52), \ 201 \ (15), \ 200 \ (100), \\ 132 \ (27), \ 91 \ (43), \ 77 \ (13), \ 51 \ (11), \ 43 \ (15). \end{split}$$

3-Hydroxy-1,6-diphenylpyrano[2,3-*c*]pyrazol-4(1*H*)-one (1i)

Recrystallization (EtOH– H_2O) afforded 377 mg (25%) of beige crystals.

Mp 241–244 °C.

IR (KBr): 3400-2400 (OH), 1666, 1647 cm⁻¹ (C=O).

MS: m/z (%) = 304 (M⁺, 0.5), 240 (26), 226 (49), 138 (50), 124 (100), 102 (22).

Anal. Calcd for C₁₈H₁₂N₂O₃ (304.30): C, 71.05; H, 3.97; N, 9.21. Found: C, 70.80; H, 3.98; N, 9.06.

3-Methoxy-1,6-diphenylpyrano[2,3-*c*]pyrazol-4(1*H*)-one (1j)

Recrystallization (EtOH) afforded 778 mg (49%) of beige crystals. Mp 208–209 °C.

IR (KBr): 1661 cm⁻¹ (C=O).

MS: m/z (%) = 319 (M⁺ + 1, 15), 318 (M⁺, 57), 317 (45), 290 (29), 289 (100), 217 (18), 216 (98), 187 (18), 133 (22), 105 (36), 102 (28), 91 (29), 83 (33), 77 (83), 51 (34).

Anal. Calcd for $C_{19}H_{14}N_2O_3\,(318.33)\cdot 0.2\,H_2O;\,C,70.89;\,H,4.51;\,N,$ 8.70. Found: C, 70.72; H, 4.56; N, 8.74.

Compounds 14e and 14f; General Procedure

To the PMB-protected 6-phenylpyrano[2,3-*c*]pyrazol-4(1*H*)-one (**1e** or **1f**, 1 mmol) was added TFA (2.85 g, 25 mmol) and the mixture was stirred at 70–75 °C for 24 h. After removal of excess TFA under reduced pressure, the residue was washed with cold acetone to afford a nearly colorless powder.

6-Phenylpyrano[2,3-c]pyrazol-4(1H)-one (14e)

Yield: 133 mg (63%); mp 309-310 °C.

IR (KBr): 3125, 3070 (NH), 1630 cm⁻¹ (C=O).

 $\begin{array}{l} \text{MS: } m/z \ (\%) = 213 \ (\text{M}^+ + 1, \, 15), \, 212 \ (\text{M}^+, \, 69), \, 121 \ (28), \, 110 \ (67), \\ 97 \ (22), \, 83 \ (20), \, 81 \ (26), \, 69 \ (52), \, 57 \ (48), \, 55 \ (53), \, 53 \ (21), \, 45 \ (22), \\ 44 \ (34), \, 43 \ (100). \end{array}$

Anal. Calcd for $C_{12}H_8N_2O_2$ (212.21)·0.2H₂O: C, 66.79; H, 3.92; N, 12.98. Found: C, 66.67; H, 3.98; N, 12.61.

3-Methyl-6-phenylpyrano[2,3-c]pyrazol-4(1H)-one (14f) Yield: 174 mg (77%); mp 314–315 °C.

IR (KBr): 3152 (NH), 1643 cm⁻¹ (C=O).

MS: m/z (%) = 227 (M⁺ + 1, 24), 226 (M⁺, 100), 124 (80), 102 (15), 67 (35).

Anal. Calcd for $C_{13}H_{10}N_2O_2$ (226.23): C, 69.02; H, 4.46; N, 12.38. Found: C, 68.76; H, 4.72; N, 12.11.

1-(5-Hydroxy-1,3-dimethyl-1*H*-pyrazol-4-yl)-3-phenylprop-2yn-1-one (12b)

From the mixture **1b/12b** the following NMR data for **12b** were unambiguously extracted:

 ^1H NMR (CDCl₃): δ = 9.25 (br s, 1 H, OH), 7.61 (m, 2 H, Ph-2,6), 7.48 (m, 1 H, Ph-4), 7.41 (m, 2 H, Ph-3,5), 3.60 (s, 3 H, NMe), 2.54 (s, 3 H, 3-Me).

¹³C NMR (CDCl₃): δ = 172.1 (C=O), 159.2 (pyrazole C-5), 147.8 (pyrazole C-3), 132.7 (Ph-2,6), 130.8 (Ph-4), 128.7 (Ph-3,5), 119.9 (Ph-1), 104.6 (pyrazole C-4), 94.7 (PhC=), 86.5 (=CCO), 32.5 (NMe), 14.1 (3-Me).

References

- The Flavonoids Advances in Research Since 1986; Harborne, J. B., Ed.; Chapman and Hall: London, 1994.
- (2) Heinisch, G.; Hollub, C.; Holzer, W. J. Heterocycl. Chem. 1991, 28, 1047.
- (3) Holzer, W.; Krca, I. Heterocycles 2003, 60, 2323.
- (4) Khan, M. A.; Pagotto, M. C.; Ellis, G. P. *Heterocycles* **1977**, *6*, 983.
- (5) Gelin, S.; Chantegrel, B.; Nadi, A. I. J. Org. Chem. 1983, 48, 4078.

- (6) Colotta, V.; Catarzi, D.; Varano, F.; Melani, F.; Filacchioni, G.; Cecchi, L.; Trincavelli, L.; Martini, C.; Lucacchini, A. *Farmaco* 1998, 53, 189.
- (7) Khan, M. A.; Ellis, G. P.; Pagotto, M. C. J. Heterocycl. Chem. 2001, 38, 193.
- (8) Garcia, H.; Iborra, S.; Primo, J.; Miranda, M. A. J. Org. Chem. 1986, 51, 4432.
- (9) McGarry, L. W.; Detty, M. R. J. Org. Chem. 1990, 55, 4349.
- (10) Bhat, A. S.; Whetstone, J. L.; Brueggemeier, R. W. *Tetrahedron Lett.* **1999**, 40, 2469.
- (11) Hepworth, J. D.; Gabbutt, C. D.; Heron, B. M. In *Comprehensive Heterocyclic Chemistry II*, Vol. 5; Katritzky, A. R.; Rees, C. W.; Scriven, E. F. V., Eds.; Elsevier: Oxford, **1996**, 431.
- (12) Jensen, B. S. Acta Chem. Scand. 1959, 13, 1668.
- (13) Eller, G. A.; Holzer, W. Heterocycles 2004, 63, 2537.
- (14) Holzer, W.; Kautsch, C.; Laggner, C.; Claramunt, R. M.; Pérez-Torralba, M.; Alkorta, I.; Elguero, J. *Tetrahedron* 2004, 60, 6791.
- (15) Begtrup, M.; Boyer, G.; Cabildo, P.; Cativiela, C.; Claramunt, R. M.; Elguero, J.; Garcia, J. I.; Toiron, C.; Vedsø, P. *Magn. Reson. Chem.* **1993**, *31*, 107.
- (16) Braun, S.; Kalinowski, H.-O.; Berger, S. 150 and More Basic NMR Experiments; Wiley-VCH: Weinheim, 1998.
- (17) Bruix, M.; Claramunt, R. M.; Elguero, J.; de Mendoza, J.; Pascual, C. Spectrosc. Lett. **1984**, *17*, 757.
- (18) Tietze, L. F.; Brumby, T.; Pretor, M.; Remberg, G. J. Org. Chem. **1988**, *53*, 810.
- (19) Veibel, S.; Eggersen, K.; Linholt, S. C. Acta Chem. Scand. 1954, 8, 768.
- (20) Curtius, T. J. Prakt. Chem. 1912, 85, 37.
- (21) Michaelis, A. Justus Liebigs Ann. Chem. 1911, 385, 1.
- (22) Weissberger, A.; Porter, H. D. J. Am. Chem. Soc. 1943, 65, 52.
- (23) Molinari, A.; Oliva, A. J. Heterocycl. Chem. 1996, 33, 479.
- (24) Bergmann, F.; Haskelberg, L. J. Am. Chem. Soc. 1941, 63, 2243.
- (25) Aroyan, A. A.; Iradyan, N. S. Arm. Khim. Zh. 1971, 24, 338; Chem. Abstr. 1971, 75, 118088.